Evidence map›Paper›PMID 31058771›Full record

Trial reportJournal of pediatric gastroenterology and nutrition2019

A Randomized Trial of Maternal Docosahexaenoic Acid Supplementation to Reduce Inflammation in Extremely Preterm Infants.

Christina J Valentine, Kelly A Dingess, Jeanne Kleiman, Ardythe L Morrow, Lynette K Rogers

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of pediatric gastroenterology and nutrition, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01732874 (Docosahexaenoic Acid Supplementation of Mothers to Improve Preterm Infant Nutrition and Immune Homeostasis), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01732874 phase1 / phase2completednot on this map

Docosahexaenoic Acid Supplementation of Mothers to Improve Preterm Infant Nutrition and Immune Homeostasis

TypeinterventionalSponsorChildren's Hospital Medical Center, CincinnatiRan2013 to 2018Enrolled27ConditionsDocosohexaenoic Acid Supplementation of Mothers toArmsExpecta 200 mg, Expecta 1 gram
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Nutrients · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 3 countries.

Christina J ValentineThe University of Cincinnati, Cincinnati, OH.
Kelly A DingessBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, The Netherlands.
Jeanne KleimanCincinnati Children's Hospital, Center for Infectious Diseases, Cincinnati.
Ardythe L MorrowThe University of Cincinnati, Cincinnati, OH.
Lynette K RogersThe Research Institute at Nationwide Children's Hospital, Columbus, OH.
Cincinnati Children's Hospital Medical Center · USNationwide Children's Hospital · USReckitt Benckiser (United Kingdom) · GBUniversity of Cincinnati · USUtrecht University · NL

Funding

LCenter for Clinical and Translational Science and TrainingUL1TR001425 · NCATS · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E., KISSELA, BRETT M · 2015 to 2024
$37.5M
DHA attenuates Inflammatory Responses Through Altering RAGE SignalingR01AT006880 · NCCIH · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI ROGERS, LYNETTE KAY · 2011 to 2015
$1.8M
Optimizing Therapeutic delivery of MicroRNAs to prevent chronic lung disease in Preterm infants.R01HD088033 · NICHD · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI ROGERS, LYNETTE KAY · 2017 to 2021
$1.6M
Cincinnati Center for Clinical and Translational Sciences and TrainingKL2TR000078 · NCATS · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E., TSEVAT, JOEL · 2012 to 2014
$1.5M
NCATS NIH HHS KL2 TR000078NCATS NIH HHS UL1 TR001425NCCIH NIH HHS R01 AT006880NICHD NIH HHS R01 HD088033
6 · The paper itself

Abstract

Maternal supplementation with 1000 mg/day docosahexaenoic acid (DHA) provides third trimester DHA accretion levels in breast milk for the preterm infant. We hypothesized that DHA supplementation to mothers providing breastmilk for extremely preterm infants would result in decreased inflammatory markers, in the infant. Mother/infant dyads (n = 27) were enrolled at birth and mothers were assigned to receive 200 or 1000 mg/day of DHA. Milk and plasma samples were analyzed for fatty acids and inflammatory markers. Decreases in inflammation were observed in both maternal and infant plasma and correlated with red blood cell (RBC) DHA levels. The fact that maternal DHA supplementation decreases infant markers of inflammation implies that DHA, delivered through breastmilk, has the potential to decrease inflammation in the infant.

Indexed as

Breast FeedingDietary SupplementsInfant, Extremely PrematureAdultCytokinesDocosahexaenoic AcidsFemaleHumansInfant, NewbornInflammationMaleMilk, HumanProspective StudiesTreatment OutcomeCytokinesDocosahexaenoic Acids

Identifiers

PMID31058771
PMCPMC6706290
OpenAlexW2944297151

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.